Inogen Inc (NASDAQ:INGN) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 1,586,018 shares, a growth of 43.3% from the September 28th total of 1,106,604 shares. Based on an average daily volume of 435,432 shares, the short-interest ratio is currently 3.6 days. Currently, 9.0% of the company’s shares are short sold.
Shares of INGN stock opened at $185.04 on Tuesday. Inogen has a 52 week low of $96.71 and a 52 week high of $287.79. The company has a market capitalization of $4.00 billion, a price-to-earnings ratio of 141.25, a price-to-earnings-growth ratio of 3.70 and a beta of 1.26.
Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Tuesday, August 7th. The medical technology company reported $0.65 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.21. Inogen had a net margin of 10.39% and a return on equity of 16.51%. The company had revenue of $97.24 million during the quarter, compared to analysts’ expectations of $81.61 million. As a group, equities research analysts forecast that Inogen will post 2.07 earnings per share for the current fiscal year.
In related news, Director Heath Lukatch sold 500 shares of Inogen stock in a transaction that occurred on Monday, August 6th. The shares were sold at an average price of $210.87, for a total value of $105,435.00. Following the completion of the sale, the director now owns 1,489 shares in the company, valued at approximately $313,985.43. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Raymond Huggenberger sold 10,500 shares of Inogen stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $196.62, for a total transaction of $2,064,510.00. Following the completion of the sale, the director now owns 8,797 shares of the company’s stock, valued at approximately $1,729,666.14. The disclosure for this sale can be found here. Insiders sold a total of 95,141 shares of company stock valued at $21,660,725 in the last quarter. 5.29% of the stock is owned by insiders.
Hedge funds have recently modified their holdings of the business. Catalyst Capital Advisors LLC purchased a new position in Inogen in the 2nd quarter valued at approximately $112,000. First Quadrant L P CA purchased a new position in Inogen in the 3rd quarter valued at approximately $134,000. Advisors Preferred LLC purchased a new position in Inogen in the 2nd quarter valued at approximately $176,000. Thompson Siegel & Walmsley LLC purchased a new position in Inogen in the 2nd quarter valued at approximately $186,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new position in Inogen in the 2nd quarter valued at approximately $216,000. 96.65% of the stock is owned by institutional investors.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Further Reading: Why is the conference call important?
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.